Evidence map›Paper›PMID 41393910›Full record

ArticleActa medica Philippina2025

Impact on Transmissibility and Case Fatality Rate of COVID-19 of the Mandatory Face Shield Use in Addition to Mask during the Pandemic: The Philippine Experience.

Mario B Prado, Manuel Peter Paul C Jorge

Abstract read
In one paragraph

Article in Acta medica Philippina, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mario B PradoDepartment of Physiology, College of Medicine, University of the Philippines Manila.
Manuel Peter Paul C JorgeDepartment of Physiology, College of Medicine, University of the Philippines Manila.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While wearing face shields and other gears to protect the facial mucous membranes not covered by face masks are proven to decrease the odds of infection in the hospital setting, there is no concrete evidence of its efficacy in the general public. Objective: To determine the effectiveness of face shield use in the general public in the local setting. Methods: This study utilized an ecological study design, with the weeks when the policy was implemented serving as the exposure variable while the weeks when the policy was not in effect, whether prior to or after, serving as control. Primary outcomes were mean incidence of COVID-19 and case fatality rate (CFR) per week. Results: When the mandatory face shield use was implemented, the mean incidence of COVID-19 per week was higher compared to weeks when it was not implemented [93 cases per 1000 population per week (ptpw) vs 65 cases, relative risk:1.43, z=-3.79, p=0.0001]. Moreover, during weeks when only less than 50% of the population was vaccinated with first dose (93 cases ptpw vs 52 cases, RR: 1.79, z=-4.3, p<0.0001) and complete doses (93 cases ptpw vs 66 cases ptpw, RR:1.41, z=-3.69, p=0.0002), the mean incidence of COVID-19 per week were statistically higher in weeks when face shield use was in effect. Controlling the status of vaccination and the predominant strain, face shield use increased the incidence of COVID-19 cases ptpw by 38 (F=13, R Conclusions: In general, although face shield use increased susceptibility to COVID-19, it decreased case fatality rate in the Philippines. However, a more robust and controlled study in the future may be needed to truly justify its recommendation for the public.

Indexed as

COVID-19epidemiologyface shieldPhilippinespublic health

Identifiers

PMID41393910
PMCPMC12697215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.